RESI Boston Panel Announcement: Early Stage Therapeutics Investors

23 Aug

By Lucy Parkinson, VP of Investor Research, LSN

The Boston area is known worldwide as a hub for early stage biotech companies, and this year’s RESI Boston event will also feature young biotech spinouts from tech hubs and universities from all around the biotech ‘First Coast’ in the US Northeast.  To commercialize their discoveries, these young companies will need to access capital.

This panel of Early Stage Therapeutic Investors aims to bring a diverse group of experts and senior decision making staff from VCs, corporate pharma, and other investor types together to discuss topics such as:

    • How they make decisions
    • What can startups do to be more attractive?
    • Areas of high need
    • Overcrowded areas
    • Common mistakes/red flags

The participants are:

  • Kuldeep Neote, Senior Director – New Ventures, Johnson & Johnson Innovation
  • Scott Weiner, Partner, Pappas Ventures
  • Bibhash Mukhopadhyay, Principal, New Enterprise Associates
  • Marta New, Partner, Agent Capital
  • Imran Babar, Chief Business Officer, Cydan

The discussion will cover topics including how the investors source and vet novel therapeutic assets, what kinds of technology are of interest to them right now, and how they as investors work with a startup to move a new drug toward commercialization.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: